Karl Zhou is a U.S.-trained medical oncologist and clinical scientist with over 30 years of experience in oncology translational medical research and drug development. Dr. Zhou has held various leadership positions with increasing responsibilities at Schering-Plough, Pfizer and i3 (an affiliate of United Healthcare). With great interest of clinical innovation (from 0 to 1) and focusing on patient centric research, Dr. Zhou has made significant contributions to the development of innovative cancer therapies, including Yervoy (ipilimumab)-the first FDA-approved CTLA-4 checkpoint inhibitor for melanoma in 2011, followed by advancements in PD-1 inhibitors (such as pembrolizumab and nivolumab) and oncolytic virus therapies (e.g., CVA-21). His expertise spans antibody therapies, targeted tyrosine kinase inhibitors (TKIs), and immuno-oncology, across multiple tumor types. He has published extensively on clinical trial data involving innovative drugs, methodologies and technologies. Dr. Zhou completed his postdoctoral and oncology clinical fellowship training at Dana-Farber Cancer Institute and Harvard Medical School under Dr. Emil Frei III, an internationally renowned clinician and a pioneer of combination chemotherapy. Dr. Zhou earned his Ph.D. in Molecular Pharmacology and cancer research from Baylor College of Medicine and graduated from Shanghai First Medical College. His areas of expertise include solid tumors such as melanoma, non-small cell lung cancer (NSCLC), breast cancer, prostate cancer, and liver cancer. He also initiated several Chinese clinical research collaboration groups, including CSCO, SHOT, and ChinaHep.